Tamar Shengelia*, Bezhan Tsinamdzgvrishvili, Kakha Nadaraia, Liluashvili K, Talakvadze T, Avaliani T, Klimiashvili Z and Rigvava L
Background: Soluble Suppression of Tumorigenicity 2 (sST2) belongs to the interleiukin-1 receptor family and has been found to be elevated in different cardiovascular conditions. However, its utility in predicting the severity of diseases or mortality outcomes has been a topic of debate. This study explores the relationship between soluble ST2 (sST2) and the prognosis of heart failure patients with reduced ejection fraction.
Methods: The study involved measuring sST2 at baseline (N=111), 1 month and 12 months in heart failure patients with reduced EF. Patients with chronic heart failure with enrolled randomly. The analysis employed a non-linear model to assess the association between sST2 and primary outcomes: Cardiovascular mortality, number of hospitalizations with diagnosis of Acute Decompensated Heart Failure (ADHF), and composite rate of death from cardiovascular disease and hospitalizations with ADHF diagnoses.
Results: The findings reveal a non-linear relationship between sST2 and the risk of cardiovascular, mortality, heart failure hospitalization and composite of cardiovascular, mortality, heart failure hospitalization. However, when considering various clinical variables, including N-terminal pro brain natriuretic peptide (NT-proBNP), only sST2 values below a specific threshold were significantly associated with outcomes.
Conclusion: Despite these findings, the inclusion of sST2 did not notably enhance the predictive ability of a model already incorporating clinical variables. The study suggests further investigation is needed to determine if monitoring sST2 can genuinely improve patients’ outcomes. Elevated sST2 concentrations and high NT-proBNP levels are stronger indications of a severe prognosis in chronic heart failure. Therefore, the combination of these two biomarkers ought to be taken into account when creating a multimarker prognostic panel.
Published Date: 2024-07-02; Received Date: 2024-06-04
